The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients

Sponsor
Xiangya Hospital of Central South University
Study ID
NCT04839237
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg per day, subcutaneous injection.
  • Liraglutide;metformin — DRUG
    The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg per day, subcutaneous injection.For metformin,during three months:0.5g each time, 3 times per day,oral.

Study Details

This studay evaluates the effect of liraglutide in the treatment of obese patients ande the influence of genetic factors on the curative effect.Half of participants will receive Liraglutide alone,while the other half who can not achieving adequate glycaemic control will receive Liraglutide and metformin in combination.

Key Dates

Start date
Dec 1, 2017
Status verified
Apr 2021
Primary completion
Dec 1, 2020
Completion
Dec 1, 2021

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    Obese patients with HbA1C lower than 9.0%,receive Liraglutide alone for 3 months.
  • Experimental: Liraglutide combined with metformin
    Obese patients with HbA1C ≥9.0%, receive Liraglutide in combination with metformin for 3 months.

Primary Outcome Measure

Weight Change at 3 months [ Time Frame: baseline and 3 months ]

Related Studies